Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

References

• Bi Y, Cao J, Jin S, Lv L, Qi L, Liu F, Geng J, Yu Y. 2016. Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. Mol Cell Biochem. 415(1–2):1–11. doi:10.1007/s11010-016-2663-8.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Sequist LV, Lin JJ. 2022. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 19(8):499–514. doi:10.1038/s41571-022-00639-9.
   PubMed Web of Science ®Google Scholar
• da Cunha Santos G, Shepherd FA, Tsao MS. 2011. EGFR mutations and lung cancer. Annu Rev Pathol. 6(1):49–69. doi:10.1146/annurev-pathol-011110-130206.
   PubMedGoogle Scholar
• Di Noia V, D’Aveni A, D’Argento E, Rossi S, Ghirardelli P, Bortolotti L, Vavassori V, Bria E, Ceresoli GL. 2021. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. ESMO Open. 6(6):100280. doi:10.1016/j.esmoop.2021.100280.
   PubMed Web of Science ®Google Scholar
• Dong J, Su SY, Wang MY, Zhan Z. 2010. Shenqi Fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res. 29(1):137. doi:10.1186/1756-9966-29-137.
   PubMedGoogle Scholar
• Fang W, Huang Y, Gu W, Gan J, Wang W, Zhang S, Wang K, Zhan J, Yang Y, Huang Y, et al. 2020. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Transl Lung Cancer Res. 9(4):1258–1267. doi:10.21037/tlcr-20-141.
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD. 2020. Targeted therapies in early stage NSCLC: hype or hope? Int J Mol Sci. 21(17):6329. doi:10.3390/ijms21176329.
   PubMed Web of Science ®Google Scholar
• Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. 2021. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 7(12):1824–1832. doi:10.1001/jamaoncol.2021.4932.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Jr., Wu YL, Paz-Ares L. 2017. Lung cancer: current therapies and new targeted treatments. Lancet. 389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8.
   PubMed Web of Science ®Google Scholar
• Huang J, Lan X, Wang T, Lu H, Cao M, Yan S, Cui Y, Jia D, Cai L, Xing Y. 2020. Targeting the IL-1beta/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC. Oncogene. 39(8):1739–1755. doi:10.1038/s41388-019-1099-5.
   PubMed Web of Science ®Google Scholar
• Khare V, Paul G, Movadat O, Frick A, Jambrich M, Krnjic A, Marian B, Wrba F, Gasche C. 2015. IL10R2 overexpression promotes IL22/STAT3 signaling in colorectal carcinogenesis. Cancer Immunol Res. 3(11):1227–1235. doi:10.1158/2326-6066.CIR-15-0031.
   PubMed Web of Science ®Google Scholar
• Kuo MH, Lee AC, Hsiao SH, Lin SE, Chiu YF, Yang LH, Yu CC, Chiou SH, Huang HN, Ko JC, et al. 2020. Cross-talk between SOX2 and TGFbeta signaling regulates EGFR-TKI tolerance and lung cancer dissemination. Cancer Res. 80(20):4426–4438. doi:10.1158/0008-5472.CAN-19-3228.
   PubMed Web of Science ®Google Scholar
• Li J, Wang JC, Ma B, Gao W, Chen P, Sun R, Yang KH. 2015. Shenqi Fuzheng injection for advanced gastric cancer: a systematic review of randomized controlled trials. Chin J Integr Med. 21(1):71–79. doi:10.1007/s11655-014-1768-8.
   PubMed Web of Science ®Google Scholar
• Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z, et al. 2014. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 20(10):2714–2726. doi:10.1158/1078-0432.CCR-13-2613.
   PubMed Web of Science ®Google Scholar
• Liu Q, Lou Y, Li L, Yang G, Cui H, Cheng Z, Li Y, Liu M, Deng C, Wan D, et al. 2022. A single-arm phase II study to evaluate efficacy and safety of first-line treatment with DCVAC/LuCa, standard of care chemotherapy and Shenqi Fuzheng injection in advanced (Stage IIIB/IV) non-small cell lung cancer patients. Integr Cancer Ther. 21:15347354221083968. 15347354221083968. doi:10.1177/15347354221083968.
   Web of Science ®Google Scholar
• Liu S, Zhang D, Wu J, Wang K, Zhao Y, Ni M, Meng Z, Zhang X. 2019. Shenqi Fuzheng injection in the treatment of breast cancer: a meta-analysis of randomized controlled trials. Integr Cancer Ther. 18:1534735418816824. 1534735418816824. doi:10.1177/1534735418816824.
   Web of Science ®Google Scholar
• Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC, Shih JY. 2015. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget. 6(12):10415–10431. doi:10.18632/oncotarget.3389.
   PubMed Web of Science ®Google Scholar
• Meng FX, Yang X, Li ML. 2022. Shenqi Fuzheng injection combined with chemotherapy for acute leukemia: a meta-analysis. Chin J Integr Med. 28(1):81–87. doi:10.1007/s11655-020-3264-7.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al. 2017. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 376(7):629–640. doi:10.1056/NEJMoa1612674.
   PubMed Web of Science ®Google Scholar
• Nagase M, Aksenov S, Yan H, Dunyak J, Al-Huniti N. 2020. Modeling tumor growth and treatment resistance dynamics characterizes different response to gefitinib or chemotherapy in non-small cell lung cancer. CPT Pharmacometrics Syst Pharmacol. 9(3):143–152. doi:10.1002/psp4.12490.
   PubMedGoogle Scholar
• Pan Z, Wang K, Chen Q, Zheng X, Song Z, Ding X. 2020. SFI enhances therapeutic efficiency of gefitinib: an insight into reversal of resistance to targeted therapy in non-small cell lung cancer cells. J Cancer. 11(2):334–344. doi:10.7150/jca.32989.
   PubMed Web of Science ®Google Scholar
• Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, et al. 2023. IL6 mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 29(7):1292–1304. doi:10.1158/1078-0432.CCR-22-3379.
   PubMed Web of Science ®Google Scholar
• Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, et al. 2010. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 5(10):1706–1713. doi:10.1097/JTO.0b013e3181f1c8de.
   PubMedGoogle Scholar
• Relli V, Trerotola M, Guerra E, Alberti S. 2019. Abandoning the notion of non-small cell lung cancer. Trends Mol Med. 25(7):585–594. doi:10.1016/j.molmed.2019.04.012.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, et al. 2012. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer patients harboring EGFR mutation. Curr Med Chem. 19(20):3337–3352. doi:10.2174/092986712801215973.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. 2023. Cancer statistics, 2023. CA Cancer J Clin. 73(1):17–48. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Su SB, Qin SY, Xian XL, Huang FF, Huang QL, ZhangDi HJ, Jiang HX. 2021. Interleukin-22 regulating Kupffer cell polarization through STAT3/Erk/Akt crosstalk pathways to extenuate liver fibrosis. Life Sci. 264:118677. doi:10.1016/j.lfs.2020.118677.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Tang J-L, Liu B-Y, Ma K-W. 2008. Traditional Chinese medicine. Lancet. 372(9654):1938–1940. doi:10.1016/S0140-6736(08)61354-9.
   PubMed Web of Science ®Google Scholar
• Vaid AK, Gupta A, Momi G. 2021. Overall survival in stage IV EGFR mutation‑positive NSCLC: comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review). Int J Oncol. 58(2):171–184. doi:10.3892/ijo.2021.5168.
   PubMed Web of Science ®Google Scholar
• Wang JL, Chen CS, Jia ZR, Miao LY, Xie J, Pan ZZ, Duan YL, Liu S, Hou MJ, Ding XS. 2022. Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations. J Cancer Res Clin Oncol. 149(7):3895–3903. doi:10.1007/s00432-022-04297-3.
   PubMed Web of Science ®Google Scholar
• Wang M, Herbst RS, Boshoff C. 2021. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 27(8):1345–1356. doi:10.1038/s41591-021-01450-2.
   PubMed Web of Science ®Google Scholar
• Wang S, Fu JL, Hao HF, Jiao YN, Li PP, Han SY. 2021. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol Res. 170:105728. doi:10.1016/j.phrs.2021.105728.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu J, Chen J, Jin S, Yao J, Yu T, Wang W, Guo R. 2019. IL-22 confers EGFR-TKI resistance in NSCLC via the AKT and ERK signaling pathways. Front Oncol. 9:1167. doi:10.3389/fonc.2019.01167.
   PubMed Web of Science ®Google Scholar
• Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. 2018. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29(suppl_1):i10–i19. doi:10.1093/annonc/mdx703.
   PubMed Web of Science ®Google Scholar
• Wu C, Liang Y, Fu F. 2022. Effect of Shenqi Fuzheng injection on leukopenia and T-cell subsets in patients with non-small cell lung cancer undergoing radiotherapy. Evid Based Complement Alternat Med. 2022:2832739.
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. 2018. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 17(1):38. doi:10.1186/s12943-018-0777-1.
   PubMed Web of Science ®Google Scholar
• Wu X, Liu Y, Zhang Z, Ou Z, Wang G, Zhang T, Long H, Lei M, Liu L, Huang W, et al. 2022. Authentication of Shenqi Fuzheng injection via UPLC-coupled ion mobility-mass spectrometry and chemometrics with kendrick mass defect filter data mining. Molecules. 27(15):4734. doi:10.3390/molecules27154734.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhao Q, Gu L, Liu C, Wang C. 2018. Shenqi Fuzheng injection reverses cisplatin resistance through mitofusin-2-mediated cell cycle arrest and apoptosis in A549/DDP cells. Evid Based Complement Alternat Med. 2018:8258246–8258212. doi:10.1155/2018/8258246.
   PubMed Web of Science ®Google Scholar
• Yan B, Shi R, Lu YY, Fang DD, Ye MN, Zhou QM. 2023. Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer. PLoS One. 18(1):e0279752. doi:10.1371/journal.pone.0279752.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ting W, Xiao L, Shufei F, Wangxiao T, Xiaoying W, Xiumei G, Boli Z. 2017. Immunoregulation of Shenqi Fuzheng injection combined with chemotherapy in cancer patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2017:5121538. doi:10.1155/2017/5121538.
   PubMed Web of Science ®Google Scholar
• Yao Y, Yang G, Lu G, Ye J, Cui L, Zeng Z, Chen J, Zhou J. 2022. Th22 cells/IL-22 serves as a protumor regulator to drive poor prognosis through the JAK-STAT3/MAPK/AKT signaling pathway in non-small-cell lung cancer. J Immunol Res. 2022:8071234–8071212. doi:10.1155/2022/8071234.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen T, Shan L. 2019. Shenqi Fuzheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis. Pharm Biol. 57(1):612–624. doi:10.1080/13880209.2019.1660383.
   PubMed Web of Science ®Google Scholar
• Zhang X, Qiu H, Li C, Cai P, Qi F. 2021. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 15(5):283–298. doi:10.5582/bst.2021.01318.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhen H, Zhao H, Zhao L, Cao B. 2022. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC Cancer. 22(1):328. doi:10.1186/s12885-022-09444-0.
   PubMed Web of Science ®Google Scholar
• Zheng X, Lu G, Yao Y, Gu W. 2019. An autocrine IL-6/IGF-1R loop mediates EMT and promotes tumor growth in non-small cell lung cancer. Int J Biol Sci. 15(9):1882–1891. doi:10.7150/ijbs.31999.
   PubMed Web of Science ®Google Scholar
• Zhu G, Zhang B, Jiang F, Zhao L, Liu F. 2019. Shenqi Fuzheng injection ameliorates fatigue-like behavior in mouse models of cancer-related fatigue. Biomed Pharmacother. 111:1376–1382. doi:10.1016/j.biopha.2019.01.042.
   PubMed Web of Science ®Google Scholar